Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer

References

• American Cancer SocietyFacts and Figures 2010 Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-and-figures-2010Accessed October 28, 2011
   Google Scholar
• The Leuprolide Study GroupLeuprolide versus diethylstilbestrol for metastatic prostate cancerN Engl J Med1984311128112866436700
   PubMed Web of Science ®Google Scholar
• VogelzangNJChodakGWSolowayMSGoserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trialUrology1995462202267624991
   PubMed Web of Science ®Google Scholar
• The Medical Research Council Prostate Cancer Working Party Investigators GroupImmediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trialBr J Urol1997792352469052476
   PubMedGoogle Scholar
• MessingEMManolaJYaoJImmediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyLancet Oncol2006747247916750497
   PubMed Web of Science ®Google Scholar
• KelleherSConwayAJHandelsmanDJBlood testosterone threshold for androgen deficiency symptomsJ Clin Endocrinol Metab2004893813381715292310
   PubMed Web of Science ®Google Scholar
• ZitzmannMFaberSNieschlagEAssociation of specific symptoms and metabolic risks with serum testosterone in older menJ Clin Endocrinol Metab2006914335434316926258
   PubMed Web of Science ®Google Scholar
• ChonJJacobsSNaslundMThe cost value of medical versus surgical hormonal therapy for metastatic prostate cancerJ Urol200016473573710953136
   PubMed Web of Science ®Google Scholar
• ConnPMCrowleyWFJrGonadotropin-releasing hormone and its analogsAnnu Rev Med1994453914058198390
   PubMed Web of Science ®Google Scholar
• KlotzLBoccon-GibodLShoreNDThe efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group Phase III study in patients with prostate cancerBJU Int20081021531153819035858
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med20113641995200521612468
   PubMed Web of Science ®Google Scholar
• PageSTLinDWMostaghelEAPersistent intraprostatic androgen concentrations after medical castration in healthy menJ Clin Endocrinol Metab2006913850385616882745
   PubMed Web of Science ®Google Scholar
• GaoWBohlCEDaltonJTChemistry and structural biology of androgen receptorChem Rev20051053352337016159155
   PubMed Web of Science ®Google Scholar
• TranCOukSCleggNJDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancerScience200932478779019359544
   PubMed Web of Science ®Google Scholar
• ShipleyWUHuntDLukkaHInitial report of RTOG 9601, a phase III trial in prostate cancer: effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with T2–3. N0 disease and elevated PSA levelsPaper presented at American Society of Clinical Oncology Genitourinary Cancers SymposiumFebruary 17–19, 2011Orlando, FL
   Google Scholar
• KlotzLO’CallaghanJDingKA phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/ SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013Paper presented at American Society of Clinical Oncology Genitourinary Cancers SymposiumFebruary 17–19, 2011Orlando, FL
   Google Scholar
• D’AmicoAVChenM-HRenshawAAAndrogen suppression and radiation vs radiation alone for prostate cancerJAMA200829928929518212313
   PubMed Web of Science ®Google Scholar
• RoachMBaeKSpeightJShort-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610J Clin Oncol20082658559118172188
   PubMed Web of Science ®Google Scholar
• JonesCUHuntDMcGowanDGRadiotherapy and short-term androgen deprivation for localized prostate cancerN Engl J Med201136510711821751904
   PubMed Web of Science ®Google Scholar
• DenhamJWSteiglerALambDSShort-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialLancet Oncol20111245145921440505
   PubMed Web of Science ®Google Scholar
• BollaMVan TienhovenGWardePExternal irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyLancet Oncol2010111066107320933466
   PubMed Web of Science ®Google Scholar
• BollaMde ReijkeTMVan TienhovenGDuration of androgen suppression in the treatment of prostate cancerN Engl J Med20093602516252719516032
   PubMed Web of Science ®Google Scholar
• HorwitzEMBaeKHanksGETen-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancerJ Clin Oncol2008262497250418413638
   PubMed Web of Science ®Google Scholar
• AusGAbrahamssonPAAhlgrenGThree-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trialBJU Int20029056156612230618
   PubMed Web of Science ®Google Scholar
• KlotzLHGoldenbergSLJewettMASLong-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomyJ Urol200317079179412913699
   PubMed Web of Science ®Google Scholar
• SchulmanCDebruyneFForsterG4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group On Neoadjuvant Treatment Of Prostate CancerEur Urol20003870671311111188
   PubMed Web of Science ®Google Scholar
• SolowayMSPareekKSharifiRNeoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year resultsJ Urol200216711211611743286
   PubMed Web of Science ®Google Scholar
• MessingEMManolaJSarosdyMImmediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancerN Engl J Med19993411781178810588962
   PubMed Web of Science ®Google Scholar
• WhittingtonRBroderickGAArgerPThe effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostateInt J Radiat Oncol Biol Phys1999441107111010421544
   PubMed Web of Science ®Google Scholar
• ShearerRDaviesJGelisterJHormonal cytoreduction and radiotherapy for carcinoma of the prostateBr J Urol1992695215241535824
   PubMedGoogle Scholar
• SnellerZHopWCarpentierPPrognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal studyJ Urol19921479629661538502
   PubMed Web of Science ®Google Scholar
• ZelefskyMLeibelSBurmanCNeoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapyInt J Radiat Oncol Biol Phys1994297557618040021
   PubMed Web of Science ®Google Scholar
• PedersonAWFricanoJCorreaDPelizzariCALiauwSLLate toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicityInt J Radiat Oncol Biol Phys2011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• HerrHWO’SullivanMQuality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapyJ Urol20001631743174610799173
   PubMed Web of Science ®Google Scholar
• van AndelGKurthKHThe impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancerEur Urol20034420921412875940
   PubMed Web of Science ®Google Scholar
• AlibhaiSMHBreunisHTimilshinaNImpact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancerJ Clin Oncol2010285038504521041715
   PubMed Web of Science ®Google Scholar
• SegalRJReidRDCourneyaKSRandomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancerJ Clin Oncol20092734435119064985
   PubMed Web of Science ®Google Scholar
• FonsecaRRajkumarSWhiteWAnemia after orchiectomyAm J Hematol1998592302339798661
   PubMed Web of Science ®Google Scholar
• ChanderSChooRDanjouxCEffect of androgen suppression on hemoglobin in prostate cancer patients undergoing salvage radiotherapy plus 2-year buserelin acetate for rising PSA after surgeryInt J Radiat Oncol Biol Phys20056271972415936551
   PubMed Web of Science ®Google Scholar
• StrumSMcDermedJScholzMAnaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockadeBr J Urol1997799339419202563
   PubMedGoogle Scholar
• GreenHJPakenhamKIHeadleyBCAltered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trialBJU Int20029042743212175403
   PubMed Web of Science ®Google Scholar
• GreenHJPakenhamKIHeadleyBCQuality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trialBJU Int20049397597915142146
   PubMed Web of Science ®Google Scholar
• JenkinsVABloomfieldDJShillingVMDoes neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot studyBJU Int200596485315963119
   PubMed Web of Science ®Google Scholar
• CherrierMMRoseALHiganoCThe effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancerJ Urol20031701808181114532781
   PubMed Web of Science ®Google Scholar
• SmithMRChanges in fat and lean body mass during androgen-deprivation therapy for prostate cancerUrology20046374274515072892
   PubMed Web of Science ®Google Scholar
• SmithMRFinkelsteinJSMcGovernFJChanges in body composition during androgen deprivation therapy for prostate cancerJ Clin Endocrinol Metab20028759960311836291
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHMcGovernFMetabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancerCancer20081122188219418348297
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHFallonMAAdipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancerUrology20087131832218308111
   PubMed Web of Science ®Google Scholar
• DockeryFBulpittCJAgarwalSTestosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemiaClin Sci200310419520112546642
   PubMed Web of Science ®Google Scholar
• EriLMUrdalPBechensteenAGEffects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasiaJ Urol19951541001047539852
   PubMed Web of Science ®Google Scholar
• LewingtonSWhitlockGClarkeRBlood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deathsLancet20073701829183918061058
   PubMed Web of Science ®Google Scholar
• StamlerJWentworthDNeatonJIs relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)JAMA198628282328283773199
   PubMed Web of Science ®Google Scholar
• SaylorPSmithMAdverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancerJ Natl Compr Canc Netw2010821122320141678
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levelsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study GroupRandomised trial of cholesterol lowering In 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study GroupPrevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levelsN Engl J Med1998339134913579841303
   PubMed Web of Science ®Google Scholar
• SmithMRMalkowiczSBChuFToremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter Phase III studyJ Clin Oncol2008261824182918398147
   PubMed Web of Science ®Google Scholar
• SmithJCBennettSEvansLMThe effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancerJ Clin Endocrinol Metab2001864261426711549659
   PubMed Web of Science ®Google Scholar
• SmithMRLeeHNathanDMInsulin sensitivity during combined androgen blockade for prostate cancerJ Clin Endocrinol Metab2006911305130816434464
   PubMed Web of Science ®Google Scholar
• KeatingNLO’MalleyAJSmithMRDiabetes and cardiovascular disease during androgen deprivation therapy for prostate cancerJ Clin Oncol2006244448445616983113
   PubMed Web of Science ®Google Scholar
• AlibhaiSMHDuong-HuaMSutradharRImpact of androgen deprivation therapy on cardiovascular disease and diabetesJ Clin Oncol2009273452345819506162
   PubMed Web of Science ®Google Scholar
• SaigalCSGoreJLKrupskiTLAndrogen deprivation therapy increases cardiovascular morbidity in men with prostate cancerCancer20071101493150017657815
   PubMed Web of Science ®Google Scholar
• TsaiHKD’AmicoAVSadetskyNAndrogen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortalityJ Natl Cancer Inst2007991516152417925537
   PubMed Web of Science ®Google Scholar
• D’AmicoAVDenhamJWCrookJInfluence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctionsJ Clin Oncol2007252420242517557956
   PubMed Web of Science ®Google Scholar
• EfstathiouJABaeKShipleyWUCardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02Eur Urol20085481682418243498
   PubMed Web of Science ®Google Scholar
• BerrutiADogliottLTerroneCChanges in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapyJ Urol20021672361236711992038
   PubMed Web of Science ®Google Scholar
• MaillefertJFSibiliaJMichelFBone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinomaJ Urol19991611219122210081873
   PubMed Web of Science ®Google Scholar
• SmithMRMcGovernFJZietmanALPamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancerN Engl J Med200134594895511575286
   PubMed Web of Science ®Google Scholar
• ShahinianVBKuoY-FFreemanJLRisk of fracture after androgen deprivation for prostate cancerN Engl J Med200535215416415647578
   PubMed Web of Science ®Google Scholar
• SmithMRLeeWCBrandmanJGonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancerJ Clin Oncol2005237897790316258089
   PubMed Web of Science ®Google Scholar
• DiamondTHWintersJSmithAThe antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockadeCancer2001921444145011745221
   PubMed Web of Science ®Google Scholar
• GreenspanSNelsonJTrumpDEffect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trialAnn Intern Med200714641642417371886
   PubMed Web of Science ®Google Scholar
• IzumiKMizokamiASugimotoKRisedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapyUrology2009731342134619371939
   PubMed Web of Science ®Google Scholar
• MichaelsonMDKaufmanDSLeeHRandomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancerJ Clin Oncol2007251038104217369566
   PubMed Web of Science ®Google Scholar
• SmithMREasthamJGleasonDMRandomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancerJ Urol20031692008201212771706
   PubMed Web of Science ®Google Scholar
• LaceyDLTimmsETanHLOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activationCell1998931651769568710
   PubMed Web of Science ®Google Scholar
• SmithMREgerdieBTorizNHDenosumab in men receiving androgen-deprivation therapy for prostate cancerN Engl J Med200936174575519671656
   PubMed Web of Science ®Google Scholar
• SmithMRMalkowiczSBChuFToremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter Phase 3 clinical studyJ Urol200817915215518001802
   PubMed Web of Science ®Google Scholar